Tag Directory / BIOTECH     showing 21–40 of 85



Cancer blood test fails to catch disease earlier in major study / Medical Express

medicalxpress - A blood test designed to find cancer early did not work as hoped in a major new study, according to the company that makes it.

#healthcare #publichealth #governmentpolicy #biotech #medicaldevices #oncology


Thursday, February 26, 2026, 7:24 pm / permalink 19851 / 7 stories in 12 days


More Research, Less Cancer: £250m raised to transform the future of cancer research / Cancer Research UK

Charlotte Mathé / cancerresearchuk - We’ve reached an incredible moment - £250m raised for our More Research, Less Cancer campaign. This milestone brings us more than halfway to our £400m goal and accelerates our mission to prevent, detect and treat cancer earlier and more effectively. The p…

#healthcare #pharmaceuticals #publichealth #biotech #drugdevelopment #oncology


Tuesday, February 24, 2026, 1:24 pm / permalink 19675 / 53 stories in 14 days


FDA Launches Framework to Accelerate Individualized Therapies for Ultra-Rare Diseases 2026 / OncoDaily

oncodaily - The U.S. Food and Drug Administration (FDA) has released groundbreaking draft guidance introducing a new regulatory framework designed to accelerate the development and approval of individualized therapies for patients with […]

#healthcare #pharmaceuticals #publichealth #governmentpolicy #biotech #drugdevelopment #fda


Tuesday, February 24, 2026, 12:25 pm / permalink 19669 / 6 stories in 14 days


Gilead to acquire cell therapy manufacturer for $7.8B / Beckers

Paige Twenter / beckershospitalreview - In a deal worth $7.8 billion, Gilead Sciences has entered a definitive agreement to acquire Arcellx, a biotech company developing a cell therapy for multiple myeloma. Gilead announced the acquisition agreement a few months after Arcellx published positive…

#healthcare #pharmaceuticals #biotech #mergersandacquisitions #corporatetakeover #drugdevelopment #fda #oncology


Monday, February 23, 2026, 4:23 pm / permalink 19605 / 7 stories in 15 days


Perioperative Enfortumab Vedotin Plus Pembrolizumab Improves EFS, OS and pCR in Patients with MIBC Who Are Ineligible for Cisplatin / ESMO

esmo - Findings from the KEYNOTE-905/EV-303 study

#healthcare #pharmaceuticals #biotech #drugdevelopment #oncology


Monday, February 23, 2026, 2:22 am / permalink 19558 / 15 stories in 16 days


Data and Decisions in Advanced NSCLC at the 2026 TTLC Symposia – IASLC / OncoDaily

oncodaily - International Association for the Study of Lung Cancer (IASLC) shared a post on LinkedIn: “2026 TTLC Symposia Event Data and Decisions in Advanced NSCLC The treatment landscape for advanced NSCLC is evolving […]

#healthcare #pharmaceuticals #biotech #drugdevelopment #oncology


Monday, February 23, 2026, 2:22 am / permalink 19557 / 23 stories in 16 days


A novel C. diff vaccine shows promise / Beckers

Mariah Taylor / beckershospitalreview - Nashville, Tenn.-based Vanderbilt Health researchers have developed a promising novel vaccine to treat Clostridioides difficile infections. Previous vaccine strategies targeted the bacterium’s primary toxins, according to a Feb. 18 system news release. Th…

#healthcare #pharmaceuticals #publichealth #biotech #drugdevelopment #vaccinesafety


Saturday, February 21, 2026, 7:21 am / permalink 19520 / 2 stories in 18 days


Novartis signs macrocyclic deal with Unnatural Products for $100M upfront / Endpoints

Kyle LaHucik / endpoints - Novartis will pay $100 million upfront to tap into a macrocyclic peptide platform from Unnatural Products, a deal that could lead to new cardiovascular disease medicines. The move allows the Swiss pharma giant to delve ...

#healthcare #pharmaceuticals #biotech #mergersandacquisitions #drugdevelopment


Saturday, February 21, 2026, 6:22 am / permalink 19517 / 2 stories in 18 days


Disc Medicine Rare Disease Drug Picked for Faster Regulatory Review Is Rejected by the FDA / MedCity

Frank Vinluan / medcitynews - The FDA asked for more data to determine whether Disc Medicine’s bitopertin is benefiting patients with erythropoietic protoporphyria, a rare blood disorder. Analysts say it’s a surprising delay considering bitopertin is one of the first drugs in a new FD…

#healthcare #pharmaceuticals #biotech #drugdevelopment #fda


Saturday, February 21, 2026, 6:22 am / permalink 19516 / 5 stories in 18 days


Predicting onset of symptomatic Alzheimerʼs disease with plasma p-tau217 clocks / Nature

Kellen K. Petersen / nature - Nature Medicine, Published online: 19 February 2026; doi:10.1038/s41591-026-04206-yPlasma p-tau217 tests used to develop clocks that predict when cognitively unimpaired individuals would develop symptoms of Alzheimerʼs disease.

#healthcare #publichealth #biotech #drugdevelopment #fda #medicaldevices


Saturday, February 21, 2026, 2:22 am / permalink 19513 / 13 stories in 18 days


Mysterious Virus Hiding Inside Common Gut Bacterium Linked to Colorectal Cancer / Discover

discovermagazine - A previously unknown virus may be the key to assessing the risk of colorectal cancer and improving diagnosis.

#healthcare #publichealth #biotech #oncology


Saturday, February 21, 2026, 12:23 am / permalink 19502 / 13 stories in 18 days


Grail’s Galleri Blood Test Falls Short in Large Cancer-Screening Study, Shares Sink 50% / MedCity

Frank Vinluan / medcitynews - Despite missing statistical significance, Grail said the observation of trending improvement suggests potential for better results with more time, so the company is extending follow up by up to a year. More detailed trial results will be submitted for pre…

#healthcare #publichealth #biotech #medicaldevices #oncology


Saturday, February 21, 2026, 12:23 am / permalink 19500 / 9 stories in 18 days


'Universal' nasal-spray vaccine protects against viruses, bacteria and allergens in mice / LiveScience

livescience - In an early animal test, a new nasal-spray vaccine has shown promise against a variety of germs and a common allergen, scientists report.

#healthcare #pharmaceuticals #publichealth #biotech #drugdevelopment #vaccinesafety


Friday, February 20, 2026, 5:22 pm / permalink 19489 / 3 stories in 18 days


Your Cat May Share the Same Cancer Genes as You, and Offer Clues for Treatment / Discover

discovermagazine - Learn how cats and humans can share key cancer mutations — and why those similarities could guide future treatment research.

#healthcare #pharmaceuticals #publichealth #biotech #drugdevelopment #oncology


Thursday, February 19, 2026, 9:23 pm / permalink 19449 / 3 stories in 19 days


Immune cells from pediatricians help uncover an antibody cocktail against RSV and hMPV / Medical Express

medicalxpress - Researchers in China recently published a study in Science Translational Medicine describing a new antibody cocktail for protection against two common viruses. The proposed preventative treatment consists of antibodies identified in pediatricians who have…

#healthcare #pharmaceuticals #publichealth #biotech #drugdevelopment #infanthealth


Thursday, February 19, 2026, 12:24 pm / permalink 19427 / 3 stories in 19 days


FDA formalizes one pivotal trial policy via NEJM perspective / Endpoints

Zachary Brennan / endpoints - Top FDA officials said that a single pivotal trial requirement will be the “new default standard” for drug approvals, a move that goes beyond the agency’s prior discretion around not requiring two trials. In a ...

#healthcare #pharmaceuticals #publichealth #governmentpolicy #biotech #drugdevelopment #fda


Thursday, February 19, 2026, 11:24 am / permalink 19422 / 3 stories in 19 days


F.D.A. Reverses Decision and Agrees to Review Moderna’s Flu Vaccine / NYT

Christina Jewett and Rebecca Robbins / nytimes - Moderna said it had held further discussions with regulators and announced that the agency would accept the company’s application for approval of its flu vaccine that uses mRNA technology.

#healthcare #pharmaceuticals #publichealth #biotech #drugdevelopment #fda #vaccinesafety


Wednesday, February 18, 2026, 9:23 am / permalink 19353 / 11 stories in 21 days


Ocular Therapeutix Eyes FDA Filing After Wet AMD Drug Tops Regeneron’s Eylea in Phase 3 Test / MedCity

Frank Vinluan / medcitynews - In the first of two Phase 3 tests, Ocular Therapeutix’s Axpaxli met the main goal of helping maintain vision in patients with the wet form of age-related macular degeneration. The Ocular drug was compared to Eylea, a blockbuster wet AMD drug marketed by R…

#healthcare #pharmaceuticals #biotech #drugdevelopment #fda


Tuesday, February 17, 2026, 9:22 pm / permalink 19334 / 3 stories in 21 days


Extracorporeal liver cross-circulation using transgenic xenogeneic pig livers with brain-dead human decedents / Nature

Abraham Shaked / nature - Nature Medicine, Published online: 09 February 2026; doi:10.1038/s41591-025-04196-3In a study of four brain-dead human decedents, extracorporeal liver cross-circulation using genetically modified pig livers provides essential hepatic functions, supporting…

#healthcare #publichealth #governmentpolicy #biotech #fda #medicaldevices


Saturday, February 14, 2026, 10:21 am / permalink 19188 / 4 stories in 25 days


New FDA-Approved Device Uses Electric Fields to Treat Pancreatic Cancer / Discover

discovermagazine - Learn more about the newly approved wearable treatment that disrupts pancreatic cancer tumor growth while letting patients continue daily life at home.

#healthcare #publichealth #biotech #fda #digitalhealth #medicaldevices #oncology #pancreaticcancer


Saturday, February 14, 2026, 10:21 am / permalink 19187 / 12 stories in 25 days


Back to Top


BIOTECH Heatmap


90 days, weeks are vertical, left is older; hover for info, click to see that day's coverage.



More Top Stories...


FDA refuses to review Moderna mRNA flu vaccine application

Moderna’s mRNA flu vaccine application has been rejected by the FDA—Moderna received a refusal‐to‐file letter while accusing the agency of shifting its review standards. Multiple reports echo this regulatory setback, fueling industry concerns over consistent, transparent decision‐making. More...


FDA CRL halts AstraZeneca’s Saphnelo prefilled pen approval

AstraZeneca’s application to market its subcutaneous prefilled pen formulation of Saphnelo for treating lupus has hit a roadblock after the FDA issued a complete response letter. The decision delays the drug’s approval and raises questions about its future in the competitive immunotherapy market. More...


CMS proposes sweeping changes to ACA marketplace plan rules

CMS has proposed a major rule reshaping Affordable Care Act marketplace policies, including loosening limits on non-standard plan designs and promoting lower-premium options such as catastrophic coverage. The agency says the changes will reduce costs and boost flexibility, while critics warn they could increase confusion and weaken consumer protections—because shopping for insurance clearly wasn’t complicated enough. More...


Tenet forecasts major ACA exchange enrollment drop and financial hit

Tenet Healthcare is warning that the expiration of enhanced Affordable Care Act premium tax credits will drive a steep reduction in ACA exchange enrollment, projecting a significant revenue impact in 2026. Despite the headwind, the company says it expects earnings growth, leaning on acuity and operational performance—because nothing calms Wall Street like “we’ll make it up somewhere else.” More...


City of Hope promotes Nisha Morris to senior marketing chief

City of Hope named Nisha Morris as Senior Vice President and Chief Marketing and Communications Officer, adding marketing leadership to its executive team. The move signals a renewed focus on brand, outreach, and patient engagement as the cancer center sharpens its communication and growth strategies. More...



NorthFeed Inc.

Disclaimer: The information provided on this website is intended for general informational purposes only. While we strive for accuracy, we do not guarantee the completeness or reliability of the content. Users are encouraged to verify all details independently. We accept no liability for errors, omissions, or any decisions made based on this information.